Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 31 (8) , 1233-1241
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal MelanomaAmerican Journal of Clinical Oncology, 2016
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialJournal of Clinical Oncology, 2015
- Radioembolization as Locoregional Therapy of Hepatic Metastases in Uveal Melanoma PatientsCardioVascular and Interventional Radiology, 2012
- Radioembolization as Salvage Therapy for Hepatic Metastasis of Uveal Melanoma: A Single-Institution ExperienceAmerican Journal of Roentgenology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Radiofrequency Ablation Induces Antigen-presenting Cell Infiltration and Amplification of Weak Tumor-induced ImmunityRadiology, 2009
- Unresectable Chemorefractory Liver Metastases: Radioembolization with90Y Microspheres—Safety, Efficacy, and SurvivalRadiology, 2008
- Unmasking of α-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing EmbolizationThe Journal of Immunology, 2007
- Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver MalignanciesJournal of Vascular and Interventional Radiology, 2006
- Epidemiology of Primary and Secondary Liver CancersSeminars in Interventional Radiology, 2006